Janux Therapeutics, Inc. (JANX)
$18.39-0.59%Close
BUYRECOVERY · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.1B
- Beta
- 2.39
- P/E (TTM)
- -10.24
- Short % float
- 9.96%
- Days to cover
- 5.9
- SI change
- -3.5%
- 1W
- +8.62%
- 1M
- +4.02%
- vs SPY 1W
- +7.46%
- vs SPY 1M
- +1.02%
Industry peers
FMP comparable companies · ranked by market cap
- LEGNSELLLegend Biotech Corporation$3.4BRECOVERYQ 2$18.62-0.48%
- CLDXSELLCelldex Therapeutics, Inc.$2.0BCRISISQ 5$29.89+2.01%
- IMNMSELLImmunome, Inc.$1.9BCRISISQ 18$19.55+1.24%
- IMTXSELLImmatics N.V.$996MCRISISQ 6$7.43+0.81%
- CGEMSELLCullinan Therapeutics, Inc.$954MCRISISQ 2$15.53+0.45%
- CTMXSELLCytomX Therapeutics, Inc.$559MCRISISQ 7$2.57+4.05%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 5
- VALUE
- 5
- GROWTH
- 16
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-6.5%
REV YoY-
ROE-10.8%
EPS YoY-
ROA-10.2%
GROSS69
OP-450
NET-322
[VALUATION]
P/E TTM-10.24
P/E FWD-
SECTOR PE20.47
INDUSTRY PE13.95
P/B1.14
P/FCF-
EV/EBITDA-10.06
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E2.26
ALTMAN Z-
CURR RATIO16.35
ND/EBITDA-
BETA2.39
Company news
FAQ
- What is LOPJLB’s current signal on JANX?
- LOPJLB’s latest quantitative signal on Janux Therapeutics, Inc. (JANX) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is JANX in?
- Janux Therapeutics, Inc. (JANX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Janux Therapeutics, Inc. (JANX) do?
- Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, wh…